



	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR		PRESENT EXTRA	RATE	ADDITIONAL FEE
TOTAL	15	-	20	=	0	\$18	\$0.00
INDEPENDENT	4	-	3	=	1	\$84	\$84.00
<input type="checkbox"/> FIRST PRESENTATION OF A MULTIPLE DEPENDENT CLAIM						\$280	\$0.00
						TOTAL	\$84.00


- ☐ Petition for () month(s) extension of time pursuant to 37 C.F.R. §§ 1.17 and 1.136(a). \$0.00 for the extension of time.
- ☐ No fee is required.
- ☒ Check(s) in the amount of \$84.00 is(are) enclosed.
- ☐ Please charge Deposit Account No. 02-2448 in the amount of \$0.00. This form is submitted in triplicate.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By


John W. Bailey, #32,881

pw
JWB/PW/jeb
0425-0854P

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

ATTACHMENT

(Rev. 09/27/01)



PATENT
0425-0854P

IN THE U.S. PATENT AND TRADEMARK OFFICE

RECEIVED

Applicant: KONDO et al. Conf.: 9474 MAR 06 2002
Appl. No.: 09/963,365 Group: 1617 TECH CENTER 1600/2900
Filed: September 27, 2001 Examiner: Karl J. STILLER
For: ANTIOXIDANT CONTAINING VITAMIN E METABOLITE

AMENDMENT UNDER 37 C.F.R. 1.111

Assistant Commissioner for Patents
Washington, DC 20231

February 25, 2002
Monday

Sir:

In response to the Office Action dated November 23, 2001,
Applicant respectfully submits the following Amendment and
Remarks as below.

03/01/2002 MWOLDER1 00000027 09963365

01 FC:102

84.00 OP

IN THE CLAIMS:

Please cancel claims 4-7 without prejudice or disclaimer
to the subject matter contained therein.

Please amend claims 1-3 as follows:

1. (Amended) A method of preventing or treating a
disease caused by oxidation in vivo, said method comprising a
step of administering a pharmacologically effective amount of
at least one compound selected from the group consisting of:

(1) 2,5,7,8-tetramethyl-2-(β -carboxyethyl)-6-
hydroxychromane, a pharmacologically acceptable salt thereof,
or a pharmacologically acceptable hydrate thereof; and

Sub
C212, improper M.L.